Role of the MET Oncogene in Human Colorectal Cancer - A Translational Study

Study Overview
=================
Brief Summary
-----------------
The MET oncogene is known to sustain the Trousseau's syndrome in murine experimental models, featuring association of carcinogenesis with a blood procoagulant disorder. MET is frequently overexpressed in colorectal cancer, a tumor where venous thromboembolism (VTE) may occur in association with poor prognosis, but the biological and genetic factors that cause VTE are still obscure. The Investigators propose to study whether in patients harboring a surgically resectable colorectal cancer the MET oncogene is expressed and may be associated with a blood thrombophilic condition that favors the onset of VTE. These data would have two main implications: (i) for the first time, a direct genetic link between the MET oncogene and a procoagulant disorder would be demonstrated in humans; (ii) the procoagulant alterations would have diagnostic/prognostic significance for the identification of patients at risk for poor outcome, and implementation of appropriate therapeutic protocols.

Official Title
-----------------
Role of the MET Oncogene in Human Colorectal Cancer. Possible Implications in the Activation of an Acquired Pro-thrombotic Condition - A Translational Study

Conditions
-----------------
Colorectal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > or = 18; age < or = 80; Clinical diagnosis of colorectal tumor by CT, MRI or endoscopy; surgically resectable tumor; Exclusion Criteria: Inclusion in other clinical protocols requiring administration of anticoagulant drugs; Life expectancy < 6 month; Clinical diagnosis of thrombophilic condition by laboratory analysis; Previously implanted Central Venous Catheter; Previous or concomitant second neoplasia; Clinical diagnosis of kidney, liver or heart failure; Inflammatory markers alteration associated with disease unrelated to neoplasia (infection, connective tissue disease etc); Severe hemostasis disorder;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| resectable colorectal cancer<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Scoring MET expression in colorectal tissue sections by immunohistochemical analysis |  | After surgical resection of the tumor, approximately 3-5 days after enrollement | 
| Scoring the expression of Plasminogen Activator Inhibitor -1 in colorectal cancer tissue sections by Immunohistochemical analysis |  | After surgical resection of the tumor, approximately 3-5 days after enrollement | 
| Scoring the expression of COX-2 in colorectal cancer tissue sections by Immunohistochemical analysis |  | After surgical resection of the tumor, approximately 3-5 days after enrollement | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
resectable colorectal cancer